SUO 2017: The Evolving Management of Advanced Renal Cell Carcinoma

Washington, DC (UroToday.com) Dr. Rana R. McKay gave a State-of-the-Art lecture providing a comprehensive presentation of the evolving management of advanced renal cell carcinoma (RCC). 

SUO 2017: Multimodal Treatment With Chemotherapy And Radical Nephroureterectomy May Improve Overall Survival In Patients With Clinically Positive Lymph Node Disease

Washington, DC (UroToday.com) Introduction: Upper tract urothelial carcinoma (UTUC) with clinical lymph node involvement (cN+) is an aggressive disease with a high incidence of mortality. The authors aimed to compare different treatment strategies for this unique entity.

SUO 2017: Point - Counterpoint: IVC Thrombectomy for Level 2 Tumor Thrombus Versus an Open Approach

Washington, DC (UroToday.com) To conclude the kidney cancer session II at the 2017 SUO, Dr. Leibovich provided a spirted discussion making the case that IVC thrombectomy for level 2 tumor thrombus cases should be performed via an open approach. Dr. Leibovich’s opening slide hit right to the point, noting that the benefits of an open approach include increased safety, lower cost, fewer complications, versatility to handle any complications, and the ability to maintain/teach open skills.

SUO 2017: Point - Counterpoint: IVC Thrombectomy for Level 2 Tumor Thrombus Versus an Open Approach

Washington, DC (UroToday.com) To conclude the kidney cancer session II at the 2017 SUO, Dr. Leibovich provided a spirted discussion making the case that IVC thrombectomy for level 2 tumor thrombus cases should be performed via an open approach. Dr. Leibovich’s opening slide hit right to the point, noting that the benefits of an open approach include increased safety, lower cost, fewer complications, versatility to handle any complications, and the ability to maintain/teach open skills.

SUO 2017: Pharmacodynamic and Pharmacokinetic Neoadjuvant Study - Hedgehog Pathway Inhibitor Sonidegib

Washington, DC (UroToday.com) Dr. Hughes and colleagues presented results of their study assessing the Hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing radical prostatectomy. The objective of this study was to determine the pharmacodynamic effects of Sonidegib in prostate tumor tissue from men with high-risk localized prostate cancer, by comparing pre-surgical core-biopsy specimens to tumor tissue harvested post-treatment at the time of prostatectomy.

SUO 2017: Testicular Cancer And Surveillance: Impact On Patient Anxiety Over Time, The Princess Margaret Cancer Centre Experience

Washington, DC (UroToday.com) Introduction: Surveillance has become a standard of care for stage 1 testicular cancer. However, little is known about its effects on anxiety and mental health. With some centers advocating adjuvant therapy for higher risk stage I disease, partially on the basis of patient anxiety, a better understanding of patients’ response to surveillance is required.

SUO 2017: Should Patients With Negative Multi-parametric MRI Avoid Prostate Biopsy?

Washington, DC (UroToday.com) Introduction: This study attempted to evaluate the detection rate and predictors of clinically significant prostate cancer (CSPCa) in patients with negative multi-parametric magnetic resonance imaging (mpMRI) prior to prostate biopsy (PBx).
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe